Outlook Therapeutics (OTLK) Cash from Financing Activities (2015 - 2026)

Outlook Therapeutics (OTLK) has reported Cash from Financing Activities for 12 consecutive years, with $6.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 62.58% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $47.2 million (up 93.81% YoY), while the FY2025 annual figure was $45.0 million, down 25.43% from the prior year.
• Cash from Financing Activities slipped to $6.9 million in Q1 2026 per OTLK's latest filing, from $15.5 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $56.1 million in Q1 2024 and bottomed at -$11.3 million in Q2 2022.
• Historically, Cash from Financing Activities has averaged $10.0 million across 5 years, with a median of $3.3 million in 2023.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities tumbled 516.26% — and 2024, when it surged 54839.96%.
• Outlook Therapeutics' Cash from Financing Activities stood at $43.8 million in 2022, then plunged by 100.01% to -$3183.0 in 2023, then soared by 54839.96% to $1.7 million in 2024, then jumped by 791.51% to $15.5 million in 2025, then slumped by 55.59% to $6.9 million in 2026.
• Business Quant data shows OTLK's Cash from Financing Activities at $6.9 million in Q1 2026, $15.5 million in Q4 2025, and $11.6 million in Q3 2025.